Stephan Schann
Chief Scientific Officer Kainova Therapeutics
Stephan Schann is Chief Scientific Officer at Kainova Therapeutics. He leads the company’s scientific strategy across its proprietary programs and collaborations with pharma partners and oversees the intellectual property portfolio supporting each of the company’s assets. Stephan has been with the organization since its origins in 2008, holding successive leadership roles including Head of Research, Director of Research & Development and Vice-President of Research & Development.
With more than 25 years of experience in biomedical research, Stephan has focused his career on the development of novel therapeutics addressing areas of unmet medical need. His significant contributions to drug discovery and development have shaped the scientific foundation of the company and its evolution over time. Before joining the organization, Stephan established and led the Medicinal Chemistry Department at Faust Pharmaceuticals and served as a senior scientist at Evotec.
Stephan holds a PhD in Medicinal Chemistry from University of Strasbourg in France.
Seminars
- Demonstrating how functional characterization can identify GPCR-targeting antibodies with differentiated biological activity
- Leveraging translational biomarker strategies to validate target engagement and support clinical development
- Showcasing the development of a CCR8-targeting antibody program designed to overcome immunosuppressive mechanisms in solid tumors
